• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment

January 12, 2017 By Sarah Faulkner

Orthocell, J&J's DePuy Synthes ink R&D deal for stem cell treatmentOrthocell (ASX:OCC) said today that it landed a research collaboration deal with Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes for its Ortho-ATI stem cell regenerative therapy.

The 2 groups are planning a collaborative study for the 1st quarter in 2017, led by Allan Wang from the University of Western Australia. In previous studies, Ortho-ATI has proven to be a durable non-surgical solution for tendon injuries that are difficult to treat, according to Orthocell. Ortho-ATI delivers cultured tendon stem cells from the patient’s healthy tendon to the patient’s damaged tendon tissue.

“This is a very exciting partnership in the continued development of Ortho-ATI and provides significant external validation of this globally relevant technology,” managing director Paul Anderson said in prepared remarks.

Ortho-ATI is available in Australia and New Zealand for patients who have failed conservative treatment options for tendinopathy, including corticosteroid injections and exercise programs.

In October, Orthocell won ethics approval for a human study evaluating its CelGro collagen soft tissue repair device for peripheral nerve regeneration. The Perth, Australia-based company’s device functions as a scaffold for orthopedic and reconstructive surgical procedures. Researchers are also studying the device’s ability to augment repair of the rotator cuff tendon, to promote bone regeneration, and guide cartilage repair in the hip joint, Orthocell said.

This week, Johnson & Johnson (NYSE:JNJ) said it will issue a report next month that will detail how much it has raised the list prices for its prescription drugs. The report will describe average increases in list prices and the average prices after discounts.

The move comes after some pharmaceutical companies, including Allergan (NYSE:AGN) and Novo Nordisk (NYSE:NVO), have pledged to keep their annual price increases to single-digit percentages. When Allergan published its “social contract” in September, CEO Brent Saunders challenged other companies to limit price increases “before we all face the impact of government regulation that stifles innovation and patient care.”

Filed Under: Featured, Regenerative Medicine, Research & Development, Stem Cells, Wall Street Beat Tagged With: DePuy Synthes, johnsonandjohnson, Orthocell

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS